Braz J Med Biol Res, February 2005, Volume 38(2) 309-313. Bone mineral density of Brazilian girls with juvenile dermatomyositis. T.C.M. de Castro 1, M.T.R.A. Terreri 1, V.L. Szejnfeld 2, C. Len 1, A.S ...

These are just a few of the health benefits of quitting smoking, but there are others, too. Quitting smoking lowers your risk of other cancers over time, including cancers of the stomach, liver, ...

Results A 5 year old boy presented with fever for 2 months associated with photosensitive malar rash, oral ulcers and myalgias.On examination, he was irritable, had malar rash, a generalised ...

We reviewed 30 patients with subungual glomus tumours of the hand operated on between 1964 and 1997. Seven patients were male and 23 were female. Their age ranged from 16 to 78 years. A transungual ...

Located in the longitudinal grooves of the proximal nail folds, periungual warts are often a source of embarrassment, deformity, and pain. When located in the lateral nail folds, they can cause ...

Parakeratosis pustulosa (PP) is a cause of distal nail inflammation and nail dystrophy that affects a single digit. It is nonpruritic and minimally painful. This distal digital dactylitis is ...

Background Macular telangiectasia type 2 (MacTel) is a neurodegenerative disease resulting in photoreceptor loss. Optical coherence tomography (OCT) reveals outer retina-associated hyperreflectivity ...

Hereditary haemorrhagic telangiectasia (HHT) is diagnosed clinically by the Curaçao Criteria of spontaneous recurrent nosebleeds, mucocutaneous telangiectasia at characteristic sites, visceral ...

The FDA has approved ENCELTO, the first treatment for macular telangiectasia type 2 (MacTel), a rare degenerative eye disease that gradually impairs central vision. ENCELTO is a surgically implanted ...

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have been no FDA-approved (or other) treatments to slow or stop vision loss.

For people diagnosed with macular telangiectasia type 2 (MacTel)-a rare and slowly progressing retinal disease-there have been no FDA-approved (or other) treatments to slow or stop vision loss.

SOUTH SAN FRANCISCO, Calif., June 03, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the ...